Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2020-12-17 Regulatory Filings
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from a Korean company (Gencurix) regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, counterparty type, and duration. Since this is a specific regulatory disclosure of a material business event that does not fit into financial reporting, dividends, or governance categories, it falls under the general regulatory filing category.
2020-12-17 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice regarding the suspension of share registration (closing of the shareholder register) for the purpose of determining shareholders for an upcoming Annual General Meeting. It does not contain the full report or proxy materials, but rather serves as a formal regulatory announcement of a corporate action. Given it is a specific regulatory notification that does not fit into the other categories like dividend or share issuance, it is classified as a general regulatory filing.
2020-12-15 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고(보고)' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients and the total number of shares. This type of filing, which concerns changes to capital-related instruments (stock options) and is submitted to regulatory bodies like the Financial Services Commission/Korea Exchange, falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance and modification of equity-linked compensation.
2020-12-11 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific employees/executives, including exercise prices, vesting periods, and valuation methods. This type of disclosure regarding the issuance of new equity-based incentives falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the potential future issuance of shares and changes to the company's capital structure.
2020-11-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives) due to stock option grants. This falls under the category of Major Shareholding Notification (MRQ) as it tracks significant ownership changes and reporting obligations.
2020-11-26 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Gencurix' (젠큐릭스) covering the period from 2020.01.01 to 2020.09.30. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.